Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641706 | 0.86 | EGLN3 (0.55) | EGLN3KCNH2EGLN1KDM4ESMN1; SMN2 | |
| SCHEMBL1642454 | 0.85 | EGLN3 (0.59) | EGLN3EGLN1EGLN2FEN1 | |
| SCHEMBL12727580 | 0.85 | EGLN3 (0.56) | EGLN3EGLN1KDM4EMEN1KMT2A | |
| SCHEMBL1642591 | 0.85 | EGLN3 (0.56) | EGLN3EGLN1EGLN2 | |
| SCHEMBL1641072 | 0.83 | EGLN3 (0.51) | EGLN3KCNH2EGLN1KDM4ESMN1; SMN2 | |
| SCHEMBL1642107 | 0.82 | EGLN3 (0.53) | EGLN3KCNH2EGLN1KDM4ESMN1; SMN2 | |
| SCHEMBL1641990 | 0.82 | EGLN3 (0.62) | EGLN3KCNH2EGLN1MEN1KMT2A | |
| SCHEMBL1640582 | 0.82 | EGLN3 (0.55) | EGLN3EGLN1EGLN2 | |
| SCHEMBL1640823 | 0.82 | EGLN3 (0.52) | EGLN3KCNH2EGLN1EGLN2 | |
| SCHEMBL1641877 | 0.81 | EGLN3 (0.70) | EGLN3EGLN1KDM4ESMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2306828-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxosmithkline LLC (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885KCNH2 3889/4885EGLN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.